NCT03943472View on ClinicalTrials.gov

BCMA Chimeric Antigen Receptor Expressing T Cells Therapy for Relapsed/Refractory Multiple Myeloma

EARLY_PHASE1UnknownINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

July 8, 2019

Primary Completion Date

November 30, 2021

Study Completion Date

May 31, 2022

Conditions
Multiple Myeloma
Interventions
BIOLOGICAL

Anti-BCMA CAR-T cells

Retroviral vector-transduced autologous T cells to express anti-BCMA CAR

DRUG

Fludarabine

30mg/m2/d

DRUG

Cyclophosphamide

300mg/m2/d

DRUG

Immune inhibitors

Immune inhibitors

Trial Locations (1)

200003

RECRUITING

Shanghai Changzheng Hospital, Shanghai

Sponsors
All Listed Sponsors
collaborator

Shanghai Changzheng Hospital

OTHER

lead

Hrain Biotechnology Co., Ltd.

INDUSTRY